KALA BIO (NASDAQ:KALA – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50, Zacks reports.
KALA BIO Trading Down 2.7 %
KALA stock opened at $6.76 on Friday. KALA BIO has a 1-year low of $4.21 and a 1-year high of $10.97. The stock’s fifty day simple moving average is $6.00 and its two-hundred day simple moving average is $6.29. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 3.07.
Wall Street Analyst Weigh In
Separately, Oppenheimer restated an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a report on Monday, August 19th.
KALA BIO Company Profile
KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Read More
- Five stocks we like better than KALA BIO
- Ride Out The Recession With These Dividend Kings
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- Find and Profitably Trade Stocks at 52-Week Lows
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- Using the MarketBeat Stock Split Calculator
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
